These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 37024611

  • 1. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M, Sirvi A, Saini V, Kashyap M, Sangamwar AT.
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
    Kassem MAA, ElMeshad AN, Fares AR.
    AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
    [Abstract] [Full Text] [Related]

  • 4. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y, Wang S, Xu Y, Wang P, Li S, Liu L, Liu M, Jin X.
    Int J Nanomedicine; 2020 May; 15():7601-7613. PubMed ID: 33116490
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ, Yue PF, Lv JL, Han J, Fu SS, Jin SX, Jin SY, Yuan HL.
    Int J Pharm; 2013 Jan 30; 441(1-2):227-33. PubMed ID: 23220096
    [Abstract] [Full Text] [Related]

  • 9. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S.
    Int J Pharm; 2015 Jan 30; 478(2):540-52. PubMed ID: 25490182
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR, Bari SB.
    Recent Pat Drug Deliv Formul; 2018 Jan 30; 12(3):162-169. PubMed ID: 30003863
    [Abstract] [Full Text] [Related]

  • 12. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S, Reddy VA, Arora S, Patel K.
    Drug Deliv Transl Res; 2016 Oct 30; 6(5):498-510. PubMed ID: 27129488
    [Abstract] [Full Text] [Related]

  • 13. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
    Rahim H, Sadiq A, Khan S, Amin F, Ullah R, Shahat AA, Mahmood HM.
    Int J Nanomedicine; 2019 Oct 30; 14():6287-6296. PubMed ID: 31496686
    [Abstract] [Full Text] [Related]

  • 14. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A, Csóka I, Tömösi F, Janáky T, Kovács A, Gáspár R, Sztojkov-Ivanov A, Ducza E, Márki Á, Szabó-Révész P, Ambrus R.
    Int J Pharm; 2020 Apr 15; 579():119166. PubMed ID: 32084574
    [Abstract] [Full Text] [Related]

  • 15. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM, Hamza MY, Abdelbary AA.
    AAPS PharmSciTech; 2018 Jul 15; 19(5):2118-2132. PubMed ID: 29700766
    [Abstract] [Full Text] [Related]

  • 16. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y.
    Int J Pharm; 2014 Dec 30; 477(1-2):251-60. PubMed ID: 25445518
    [Abstract] [Full Text] [Related]

  • 17. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ, Gajera BY, Dave RH.
    Drug Dev Ind Pharm; 2018 Dec 30; 44(12):1942-1952. PubMed ID: 30027778
    [Abstract] [Full Text] [Related]

  • 18. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
    Hui-Rong XI, Hui-Ping MA, Ke-Ming C, Xiao-Shuan L.
    Zhongguo Zhong Yao Za Zhi; 2020 Oct 30; 45(20):4902-4908. PubMed ID: 33350263
    [Abstract] [Full Text] [Related]

  • 19. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
    Pınar SG, Canpınar H, Tan Ç, Çelebi N.
    Eur J Pharm Sci; 2022 Apr 01; 171():106123. PubMed ID: 35017012
    [Abstract] [Full Text] [Related]

  • 20. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
    Boscolo O, Flor S, Salvo L, Dobrecky C, Höcht C, Tripodi V, Moretton M, Lucangioli S.
    Pharmaceutics; 2023 Jul 28; 15(8):. PubMed ID: 37631251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.